Teachers Advisors LLC raised its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 23.8% during the 4th quarter, HoldingsChannel reports. The firm owned 5,281,872 shares of the biopharmaceutical company’s stock after purchasing an additional 1,016,786 shares during the period. Teachers Advisors LLC’s holdings in Bristol-Myers Squibb were worth $323,673,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Delphi Private Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $108,000. Atlantic Trust LLC purchased a new position in shares of Bristol-Myers Squibb in the second quarter worth $111,000. Massey Quick Simon & CO. LLC lifted its holdings in shares of Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares in the last quarter. NuWave Investment Management LLC purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $119,000. Finally, Horan Capital Advisors LLC. purchased a new position in shares of Bristol-Myers Squibb in the third quarter worth $122,000. 71.53% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb stock opened at $60.88 on Monday. The firm has a market cap of $99,391.66, a P/E ratio of 20.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.96. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb has a 52-week low of $51.56 and a 52-week high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the prior year, the firm earned $0.63 earnings per share. Bristol-Myers Squibb’s revenue was up 3.9% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb will post 3.22 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
Several equities analysts have recently commented on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price on the stock. in a report on Friday, December 22nd. BMO Capital Markets set a $51.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Wednesday, February 14th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, January 29th. TheStreet downgraded shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. Finally, Jefferies Group set a $70.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Friday, March 23rd. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $66.68.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/09/teachers-advisors-llc-has-323-67-million-holdings-in-bristol-myers-squibb-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.